10-Q: Guided Therapeutics Reports Q1 2026 Financials, Extends Debt

Guided Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, operational updates, and a significant promissory note extension with its CEO.

Summary

• Guided Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026.
• The company experienced a net loss attributable to common stockholders of $1,013,441, or $(0.01) per basic and diluted share.
• Total assets were $1,604,000, with current assets of $911,000 and non-current assets of $693,000.
• Total liabilities were $6,780,000, with current liabilities of $5,962,000 and long-term liabilities of $818,000.
• Stockholders' deficit was $(5,176,000).
• Cash and cash equivalents increased to $369,000 from $63,000 at the end of the previous year.
• The company raised $922,475 in net cash from financing activities, primarily from warrant exercises ($980,000) and note issuances ($187,550).
• A significant event was the extension of a promissory note to CEO Mark L. Faupel, with a new principal amount of $133,511.74, 6% simple annual interest, and a maturity date of August 18, 2027.
• This note includes acceleration clauses if the company secures $4.0 million in financing or maintains $4.0 million in cash on hand.
• The company continues to face going concern risks due to its accumulated deficit of $158.0 million and recurring operating losses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, rising G&A expenses, and the ongoing need for significant capital, despite some positive cash flow from financing activities and progress on regulatory fronts.

Positives

• Increase in cash and cash equivalents to $369,000 from $63,000.
• Successful financing activities providing $922,475 in net cash, driven by $980,000 from warrant exercises.
• Completion of patient enrollment and data analysis for the US FDA clinical trial, with results expected to exceed FDA expectations.
• Progress in obtaining NMPA approval in China, with potential approval in Q3 or Q4 2026.
• Secured a new promissory note with CEO Mark L. Faupel, extending debt maturity and providing clarity on repayment terms.
• The company has established an auxiliary manufacturing site in Hungary to mitigate tariff risks.

Negatives

• Net loss attributable to common stockholders of $1,013,441 for the quarter.
• Accumulated deficit of $158.0 million as of March 31, 2026.
• Working capital deficit of approximately $5.1 million.
• Disclosure controls and procedures were found to be ineffective due to material weaknesses in internal control over financial reporting.
• The 10% Senior Unsecured Convertible Debenture remains in default and accrues interest at a default rate of 18%.
• The company requires significant additional capital to fund operations and regulatory processes, with an estimated need of $2.4 million over the next 12 months.
• Failure to raise sufficient capital could lead to curtailment of operations, unfavorable agreements, or bankruptcy protection.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to its recurring losses, accumulated deficit, and need for future capital.
• The company may not be successful in growing sales for its products, and required regulatory clearances or approvals may not be obtained in a timely manner, or at all.
• Products may not gain market acceptance, and the company may not generate significant revenues or achieve profitability.
• The development and commercialization of products require substantial expenditures, and operating losses are expected to continue.
• The conflict in Ukraine and geopolitical tensions in the Middle East create uncertainty that could impact supply chains, distribution, and regulatory interactions.
• Changes in U.S. or foreign governmental actions related to tariffs, tax policies, or international trade agreements could materially adversely affect the business.
• The company's primary reliance on the Chinese market for revenue makes it vulnerable to trade disputes and regulatory changes in China.
• The effectiveness and market acceptance of LuViva, and the ability to generate sufficient sales revenues, are subject to uncertainty.
• The company faces risks related to obtaining regulatory approvals in various international markets, including the US FDA and China's NMPA.
• Manufacturing scale-up and the availability of critical components pose potential challenges.
• The company's intellectual property position and ability to protect proprietary information are critical.
• The company is dependent on potential strategic partners or outside investors for funding, development, and distribution.

Future Outlook

The company expects operating losses to continue for the foreseeable future as it expends substantial resources on product commercialization, regulatory approvals, and building its capabilities. They estimate needing approximately $2.4 million to fund operations over the next 12 months. Potential sales of approximately $1.0 million are expected within the next twelve months based on existing purchase orders and discussions, contingent on Chinese regulatory approval. The company anticipates filing its US FDA PMA application in the second quarter of 2026 and expects potential NMPA approval in the third or fourth quarter of 2026.

Management Comments

• The company's prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry.
• We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.
• We believe the results [of the US FDA clinical trial] exceed those expected by FDA, thus increasing the likelihood of approval.
• Although SMI continues to work with partners in China to pursue NMPA approval, we are no longer obligated to work with SMI and have instead increased our engagement with HDMT and YMIC.

Industry Context

StockSavvy.ai notes that Guided Therapeutics operates in the highly competitive and capital-intensive medical device industry, characterized by long development cycles, significant regulatory hurdles, and a high failure rate. The company's focus on non-invasive cancer detection technology, particularly for cervical cancer, positions it within a growing segment of the healthcare market driven by demand for early detection and less invasive procedures. However, the company's ongoing financial challenges and reliance on external funding highlight the typical funding pressures faced by early-stage medical device companies.

Comparison to Industry Standards

• The company's net loss of $1,013,441 for the quarter and accumulated deficit of $158.0 million are significant, reflecting the high costs associated with medical device development and regulatory approval, which is common for companies at this stage.
• The need for $2.4 million in funding over the next 12 months is substantial for a company with limited revenue, a common challenge in the biotech and medical device sectors where R&D and clinical trials are expensive.
• The company's reliance on convertible debt and warrants for financing is a standard practice in the industry to attract capital, but it also introduces potential dilution for existing shareholders, a factor often scrutinized by investors in this sector.
• The extended timeline for regulatory approvals (FDA and NMPA) is typical for medical devices, with companies often facing delays and uncertainties, as seen with Guided Therapeutics' ongoing efforts.

Corporate Governance

Legal Proceedings

• Management believes that the disposition of pending legal proceedings and claims, individually or in aggregate, are not expected to have a material adverse effect on the Company's financial condition.

Related Party Transactions

• Promissory note to Dr. Mark Faupel (CEO) extended with a principal amount of $133,511.74, 6% interest, maturing August 18, 2027, with acceleration clauses.
• Dr. Faupel's deferred compensation balance totaled approximately $510,000, accruing 6% interest and convertible into common stock at $0.25 per share.
• Dr. John Imhoff (Board member) converted $40,000 principal and $4,000 accrued interest from a contingently convertible promissory note into common stock.
• Dr. John Imhoff received 25,338 shares of common stock for payment of accrued dividends on Series E Preferred Stock.
• Dr. John Imhoff also received 400,000 shares of common stock upon conversion of 100 shares of Series E Preferred Stock.
• Promissory notes to Dr. Mark Faupel and Dr. Gene Cartwright with aggregate balances of approximately $495,000, including accrued interest.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to convertible debt and warrants, and ongoing need for capital raises. The company's financial performance and future prospects directly impact shareholder value.
• Creditors: The company has significant debt obligations, including defaulted convertible debentures and notes payable to related parties. The extension of the CEO's note provides some clarity but also highlights ongoing debt servicing.
• Employees: The company's financial condition and going concern risks may create uncertainty regarding job security. Stock-based compensation is a component of employee remuneration.
• Management: The CEO's note extension and compensation arrangements are detailed, indicating continued involvement and financial ties to the company.

Next Steps

• File clinical results with FDA in the second quarter of 2026.
• Potential NMPA approval in the third or fourth quarter of 2026.
• Continue efforts to raise approximately $2.4 million in capital over the next 12 months.
• Fulfill existing orders and pursue new sales opportunities in the US, China, and Europe.
• Complete the clinical study in Turkey funded by the MOH, expected to conclude in 2026.
• Resolve payment and parts sourcing issues with YMIC for LuViva devices.

Key Dates

Recommendation

The company shows some positive signs with progress on regulatory approvals and increased cash from financing activities. However, the significant net loss, substantial accumulated deficit, ongoing need for capital, and material weaknesses in internal controls present considerable risks. A 'hold' recommendation is appropriate, suggesting investors monitor regulatory progress and capital raising efforts closely before considering a more definitive stance.

Keywords

Guided Therapeutics, Form 10-Q, Quarterly Report, Medical Device, LuViva, Cervical Cancer Detection, FDA Approval, NMPA Approval, Promissory Note, Convertible Debt, Going Concern, Financial Results